Clinical experience with the angiotensin converting enzyme inhibitor captopril.
1. Sixty-two patients (nineteen mild-moderate, forty-three severe hypertension) were treated with captopril. 2. Blood pressure was controlled long term (with/without diuretics/beta-adrenoreceptor blocking drugs) in sixteen out of nineteen patients with mild-moderate hypertension. Two patients complained of dysguesia. 3. Long term control (with/without other drugs) was achieved in thirty out of forty-three patients with severe or accelerated hypertension, many of whom had associated renal or renovascular disease. Side-effects were common: five rash, five dysguesia, two rash and dysguesia, two reversible agranulocytosis. 4. Six patients had a profound pressure fall after an initial dose of captopril 25 mg and one developed acute oliguric renal failure. Treatment should be commenced at low doses in severely hypertensive patients.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced; D000806:Angiotensin-Converting Enzyme Inhibitors; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000097:blood; D011392:Proline / Q000031:analogs & derivatives*; D012083:Renin / Q000097:blood
D000806:Angiotensin-Converting Enzyme Inhibitors; D011392:Proline; D002216:Captopril; D012083:Renin; D011188:Potassium